FDA recall record

WAL-DRAM 2 (meclizine Hydrochloride) 25 mg tablets recall — FDA D-0324-2020

Subpotent Drug

Class IIIclassification
D-0324-2020official record ID
Nov 20, 2019report date

Recall record at a glance

Official recordD-0324-2020
CategoryDrug Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmSato Pharmaceutical Inc.
Report dateNov 20, 2019
Recall initiation dateOct 1, 2019
Quantitya) 112,104 units b) 24,696 units
LocationTorrance, CA, United States

Official product description

WAL-DRAM 2 (meclizine Hydrochloride) 25 mg tablets, packaged in a) 12 count (NDC 0363-1407-01, UPC 3 11917-18328 2 ) and b) 18-count boxes (NDC 0363-1407-02, UPC 3 11917-20318 8) Distributed by Sato Pharmaceutical INC. 20695 S. Western Ave., Suite 240 Torrence, CA 90501,

Why the product was recalled

Subpotent Drug

Distribution information

Nationwide within the United States, Guam and Saipan

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.

DrugMay 31, 2017

SATO CLEAR recall — FDA D-0855-2017

Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

Class IIFDA: TerminatedSato Pharmaceutical Inc.